Circulating Tumor HPV DNA in Patients With Head and Neck Carcinoma

被引:5
|
作者
Mijares, Kevin [1 ]
Ferrandino, Rocco [2 ]
Chai, Raymond [2 ]
Roof, Scott [2 ]
Bhardwaj, Swati [3 ]
Posner, Marshall [4 ]
Westra, William H. [3 ,5 ]
机构
[1] Mt Sinai West, Dept Pathol, New York, NY USA
[2] Mt Sinai Hosp, Dept Otolaryngol Head & Neck Surg, Icahn Sch Med, New York, NY USA
[3] Mt Sinai Hosp, Dept Pathol, Icahn Sch Med, New York, NY USA
[4] Mt Sinai Hosp, Icahn Sch Med, Dept Med, Div Hematol & Med Oncol, New York, NY USA
[5] 1468 Madison Ave,Annenberg Bldg 15-54, New York, NY 10029 USA
关键词
liqued biopsy; HPV-associated head and neck cancer; oropharyngeal squamous cell carcinoma; human papillomavirus; NavDx; HUMAN-PAPILLOMAVIRUS; OROPHARYNGEAL CARCINOMA; SURROGATE MARKER; PLASMA; CANCER; SYSTEM;
D O I
10.1097/PAS.0000000000002134
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Circulating tumor human papillomavirus DNA (ctHPVDNA) testing using digital-droplet polymerase chain reaction (PCR) detects fragments of tumor-modified human papillomavirus (HPV) in the plasma of patients with HPV-associated head and neck squamous cell carcinomas (HNSCCs). Its impact on tumor surveillance and primary diagnosis is limited by unresolved issues relating to sensitivity and specificity. The study population consisted of patients with HNSCC who had undergone ctHPVDNA testing. HPV status was determined by p16 immunohistochemistry and PCR-HPV genotyping on the tumor samples. For discrepant cases (HPV-positive/ctHPVDNA-negative), HPV status was confirmed by RNA in situ hybridization and, when possible, targeted single-nucleotide polymorphisms genotyping. A total of 167 patients had ctHPVDNA testing, and 141 tumors were HPV positive by p16 immunohistochemistry and PCR genotyping. Genotypes included types 16 (91.5%), 33 (4.3%), 35 (2.1%), and 18 (2.1%). ctHPVDNA was detected in 133 (94.3%) of HPV-positive HNSCCs but in none of the HPV-negative HNSCCs. Four of the 5 p16-positive cases that were negative by PCR and ctHPVDNA were positive by RNA in situ hybridization, and in 2 of these cases, rare high-risk genotypes were identified. ctHPVDNA had a sensitivity of 91.7%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 63.6%. The likelihood that patients with HPV-positive HNSCC have detectable ctHPVDNA is high. Non-HPV16 genotypes contribute to discrepancies but only in a small subset of cases. This finding validates ongoing efforts to use ctHPVDNA as a surveillance tool, and even as a primary diagnostic assay in patients presenting with masses in the neck and/or oropharynx.
引用
收藏
页码:80 / 87
页数:8
相关论文
共 50 条
  • [21] Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer
    Rettig, Eleni M.
    Faden, Daniel L.
    Sandhu, Shaiba
    Wong, Kristine
    Faquin, William C.
    Warinner, Chloe
    Stephens, Phil
    Kumar, Sunil
    Kuperwasser, Charlotte
    Richmon, Jeremy D.
    Uppaluri, Ravindra
    Varvares, Mark
    Sethi, Rosh
    Hanna, Glenn J.
    Sroussi, Herve
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (07) : 1081 - 1085
  • [22] Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma
    Jen Y Lee
    Isaac Garcia-Murillas
    Rosalind J Cutts
    David Gonzalez De Castro
    Lorna Grove
    Tara Hurley
    Fuqiang Wang
    Christopher Nutting
    Katie Newbold
    Kevin Harrington
    Nicholas Turner
    Shreerang Bhide
    British Journal of Cancer, 2017, 117 : 876 - 883
  • [23] Predicting response to radical (chemo) radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma
    Lee, Jen Y.
    Garcia-Murillas, Isaac
    Cutts, Rosalind J.
    De Castro, David Gonzalez
    Grove, Lorna
    Hurley, Tara
    Wang, Fuqiang
    Nutting, Christopher
    Newbold, Katie
    Harrington, Kevin
    Turner, Nicholas
    Bhide, Shreerang
    BRITISH JOURNAL OF CANCER, 2017, 117 (06) : 876 - 883
  • [24] Correlation between circulating tumor DNA and tumor volume in head and neck cancer
    Okifo, Oghenefejiro
    Wu, Vivian
    Tam, Samantha
    Al Khatib, Sondos
    Siddiqui, Farzan
    CLINICAL CANCER RESEARCH, 2023, 29 (18)
  • [25] Carcinoma of the head and neck in the HPV era
    Cardesa, A.
    Nadal, A.
    ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA, 2011, 20 (03): : 161 - 173
  • [26] Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN)
    Galot, Rachel
    Machiels, Jean-Pascal H.
    CANCER TREATMENT REVIEWS, 2020, 85
  • [27] Mutated TP53 in Circulating Tumor DNA as a Risk Level Biomarker in Head and Neck Squamous Cell Carcinoma Patients
    Kampel, Liyona
    Feldstein, Sara
    Tsuriel, Shlomo
    Hannes, Victoria
    Neiderman, Narin N. Carmel
    Horowitz, Gilad
    Warshavsky, Anton
    Leider-Trejo, Leonor
    Hershkovitz, Dov
    Muhanna, Nidal
    BIOMOLECULES, 2023, 13 (09)
  • [28] Feasibility of Circulating Cell-Free Tumor DNA as a Biomarker in Head and Neck Squamous Cell Carcinoma
    Egyud, Matthew R.
    Saunders, Stefanie S.
    Devaiah, Anand K.
    Jalisi, Scharukh
    Godfrey, Tony E.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (04) : S191 - S192
  • [29] The effect of circulating tumor DNA on the prognosis of patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis
    Yang, Ruoyi
    Li, Teng
    Zhang, Sicheng
    Shui, Chunyan
    Ma, Hong
    Li, Chao
    BMC CANCER, 2024, 24 (01)
  • [30] Detectable Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA in Non-Oropharyngeal Head and Neck Cancers
    Duffy, E. W., III
    Kaczmar, J.
    Albergotti, W.
    Kejner, A.
    Newman, J. G.
    Graboyes, E. M.
    Tamblyn, A.
    Chera, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E28 - E29